Woburn-based CONTINUUS Pharmaceuticals has won a $69.3 million U.S. government contract to facilitate domestic production of three medicines used to treat critically ill patients, including those with COVID-19. “…In addition to streamlining continuous, environmentally friendly, and cost-efficient production of these medicines, this contract will help us build a state-of-the-art facility that will address urgent pharmaceutical supply chain […]

Biogen and Eisai have announced that the FDA has extended the review period by three months for the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. The new action date is June 7, 2021. If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for […]

Thermo Fisher Scientific has announced plans to acquire Mesa Biotech, a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction which is expected to take place in Q1 2021. […]

BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, has announced the acquisition of an existing 162,000 square foot office building and adjacent 7.5 acre site at Assembly Square in Somerville. The Assembly Square campus will be developed in phases and represents a total of 1.3 million square […]

Fujifilm Corporation and The Massachusetts Center for Advanced Biological Innovation and Manufacturing (CABIM) have secured 76M in financing and signed a lease for a 40,000 square-foot site in Watertown at The Arsenal on the Charles. The Center will advance research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. Fujifilm Diosynth Biotechnologies, […]

Echoing a nationwide trend, local life sciences companies continue to attract record funding as investors respond to the industry’s recent pandemic-fueled successes and heightened visibility: Since launching a year ago, Cambridge-based EQRx has raised approximately $750M including a recent $500M Series B financing to advance its mission of bringing new medicines to patients and healthcare […]

Dewpoint Therapeutics has announced a new research collaboration with Pfizer for the development of potential therapeutics for the treatment of myotonic dystrophy type 1 (DM1), a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and […]

bluebird bio has announced its intent to separate its severe genetic disease (SGD) and oncology businesses into differentiated and independent publicly traded companies. bluebird bio, Inc. will retain focus on SGD and will launch its oncology business (“Oncology Newco”) as a new entity. Upon completion of the separation, current chief bluebird, Nick Leschly, will lead Oncology […]

Agios Pharmaceuticals has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company for which it will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash. Agios plans to move forward with a singular focus on its genetically defined disease portfolio, including […]

Robert Coughlin, departing President and CEO of the Massachusetts Biotechnology Council, will join the JLL Brokerage team as Managing Director in the firm’s Life Sciences industry practice in early 2021. JLL is a registered trademark of Jones Lang LaSalle, a Fortune 500 real estate and investment management company with annual revenue of $18.0 billion in […]